KPTI
Income statement / Annual
Last year (2024), Karyopharm Therapeutics Inc.'s total revenue was $145.24 M,
a decrease of 0.55% from the previous year.
In 2024, Karyopharm Therapeutics Inc.'s net income was -$76.42 M.
See Karyopharm Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$145.24 M |
$146.03 M |
$157.07 M |
$209.82 M |
$108.09 M |
$40.89 M |
$30.34 M |
$1.61 M |
$154.00 K |
$250.00 K |
| Cost of Revenue |
$6.01 M
|
$4.94 M
|
$5.21 M
|
$3.40 M
|
$2.71 M
|
$2.41 M
|
$161.37 M
|
$107.27 M
|
$86.94 M
|
$97.74 M
|
| Gross Profit |
$139.23 M
|
$141.09 M
|
$151.86 M
|
$206.42 M
|
$105.38 M
|
$38.49 M
|
-$131.04 M
|
-$105.67 M
|
-$86.78 M
|
-$97.49 M
|
| Gross Profit Ratio |
0.96
|
0.97
|
0.97
|
0.98
|
0.97
|
0.94
|
-4.32
|
-65.84
|
-563.53
|
-389.98
|
| Research and Development Expenses |
$143.23 M
|
$138.75 M
|
$148.66 M
|
$160.84 M
|
$150.81 M
|
$122.34 M
|
$161.37 M
|
$107.27 M
|
$86.94 M
|
$97.74 M
|
| General & Administrative Expenses |
$115.44 M
|
$131.88 M
|
$145.40 M
|
$143.85 M
|
$126.42 M
|
$0.00
|
$48.85 M
|
$24.87 M
|
$23.95 M
|
$21.58 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$115.44 M
|
$131.88 M
|
$145.40 M
|
$143.85 M
|
$126.42 M
|
$105.42 M
|
$48.85 M
|
$24.87 M
|
$23.95 M
|
$21.58 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$33.00 K
|
-$81.00 K
|
$10.00 K
|
-$2.00 K
|
| Operating Expenses |
$258.67 M
|
$270.63 M
|
$294.06 M
|
$304.69 M
|
$277.23 M
|
$227.76 M
|
$210.22 M
|
$132.14 M
|
$110.89 M
|
$119.33 M
|
| Cost And Expenses |
$264.68 M
|
$275.57 M
|
$299.28 M
|
$308.09 M
|
$279.94 M
|
$230.17 M
|
$210.22 M
|
$132.14 M
|
$110.89 M
|
$119.33 M
|
| Interest Income |
$7.40 M
|
$10.94 M
|
$2.36 M
|
$582.00 K
|
$2.82 M
|
$5.42 M
|
$4.03 M
|
$1.70 M
|
$1.28 M
|
$897.00 K
|
| Interest Expense |
$37.42 M
|
$23.82 M
|
$25.00 M
|
$26.05 M
|
$27.14 M
|
$15.65 M
|
$2.49 M
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$340.00 K
|
$530.00 K
|
$621.00 K
|
$789.00 K
|
$972.00 K
|
$974.00 K
|
$735.00 K
|
$713.00 K
|
$717.00 K
|
$634.00 K
|
| EBITDA |
-$38.60 M |
-$118.42 M |
-$139.31 M |
-$96.99 M |
-$167.85 M |
-$182.93 M |
-$175.15 M |
-$128.21 M |
-$108.72 M |
-$118.44 M |
| EBITDA Ratio |
-0.27
|
-0.81
|
-0.89
|
-0.46
|
-1.55
|
-4.47
|
-5.77
|
-79.88
|
-705.98
|
-473.77
|
| Operating Income Ratio |
-0.82
|
-0.89
|
-0.91
|
-0.47
|
-1.59
|
-4.63
|
-5.93
|
-81.33
|
-719.04
|
-476.3
|
| Total Other Income/Expenses Net |
$43.08 M
|
-$13.24 M
|
-$22.72 M
|
-$25.55 M
|
-$24.11 M
|
-$10.28 M
|
$1.50 M
|
$1.62 M
|
$1.29 M
|
$895.00 K
|
| Income Before Tax |
-$76.37 M
|
-$142.78 M
|
-$164.92 M
|
-$123.82 M
|
-$195.96 M
|
-$199.55 M
|
-$178.38 M
|
-$128.92 M
|
-$109.44 M
|
-$118.18 M
|
| Income Before Tax Ratio |
-0.53
|
-0.98
|
-1.05
|
-0.59
|
-1.81
|
-4.88
|
-5.88
|
-80.32
|
-710.64
|
-472.72
|
| Income Tax Expense |
$57.00 K
|
$323.00 K
|
$369.00 K
|
$268.00 K
|
$309.00 K
|
$40.00 K
|
$26.00 K
|
$63.00 K
|
$139.00 K
|
-$895.00 K
|
| Net Income |
-$76.42 M
|
-$143.10 M
|
-$165.29 M
|
-$124.09 M
|
-$196.27 M
|
-$199.59 M
|
-$178.41 M
|
-$128.98 M
|
-$109.58 M
|
-$118.18 M
|
| Net Income Ratio |
-0.53
|
-0.98
|
-1.05
|
-0.59
|
-1.82
|
-4.88
|
-5.88
|
-80.36
|
-711.54
|
-472.72
|
| EPS |
-9.41 |
-18.79 |
-30.28 |
-24.75 |
-40.87 |
-48.32 |
-47.1147 |
-42.15 |
-43.8 |
-49.8 |
| EPS Diluted |
-9.41 |
-18.79 |
-30.28 |
-24.75 |
-40.87 |
-48.32 |
-47.1147 |
-42.15 |
-43.8 |
-49.8 |
| Weighted Average Shares Out |
$8.12 M
|
$7.61 M
|
$5.46 M
|
$5.01 M
|
$4.80 M
|
$4.13 M
|
$3.79 M
|
$3.06 M
|
$2.50 M
|
$2.37 M
|
| Weighted Average Shares Out Diluted |
$8.12 M
|
$7.61 M
|
$5.46 M
|
$5.01 M
|
$4.80 M
|
$4.13 M
|
$3.79 M
|
$3.06 M
|
$2.50 M
|
$2.37 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
